New inhaled therapy targets lung scarring in early trial
NCT ID NCT05537025
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an inhaled drug called ARO-MMP7 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The main goal was to check safety and how the body handles the drug. About 105 participants took part, receiving either the drug or a placebo via a nebulizer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARO-MMP7 inhalation solution
What this could lead to
If successful, this could point toward a new inhaled treatment to slow or control idiopathic pulmonary fibrosis, a serious lung-scarring disease.
What could go wrong
This is an early phase 1/2a trial focused on safety, so it is too soon to know if it works. The drug may cause side effects or fail to improve lung function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Copenhagen, DA-2100, Denmark
-
Research Site 1
Ancona, 60126, Italy
-
Research Site 1
Auckland, 1010, New Zealand
-
Research Site 1
Ulsan, 44033, South Korea
-
Research Site 1
Barcelona, 08017, Spain
-
Research Site 1
Birmingham, B15 2GW, United Kingdom
-
Research Site 2
Odense, DK-5000, Denmark
-
Research Site 2
Florence, 50134, Italy
-
Research Site 2
Christchurch, 08011, New Zealand
-
Research Site 2
Seoul, 05505, South Korea
-
Research Site 2
Oviedo, 33011, Spain
-
Research Site 2
Edinburgh, EH16 4SA, United Kingdom
-
Research Site 3
Milan, 20122, Italy
-
Research Site 3
Soeul, 21565, South Korea
-
Research Site 3
Santander, Cantabria, 39008, Spain
-
Research Site 3
Manchester, M8 5RB, United Kingdom
-
Research Site 4
Milan, 20122, Italy
-
Research Site 4
Manchester, M23 9QZ, United Kingdom
-
Research Site 5
Milan, 20123, Italy